Chart-Typ:
Zeitraum:
| T1 Energy Inc.: T1 Energy Reports Second Quarter 2025 Results | AUSTIN, Texas and NEW YORK, Aug. 20, 2025 (GLOBE NEWSWIRE) -- T1 Energy Inc. (NYSE: TE) ("T1," "T1 Energy," or the "Company") has reported financial and operating results for the second quarter 2025... ► Artikel lesen |
| Corning, T1 Energy agree to U.S. domestic solar polysilicon, wafer supply deal | The partnership supports a full domestic energy supply chain from raw polysilicon to finished solar panels. From pv magazine USA T1 Energy signed a deal to purchase Corning's purified polysilicon and... ► Artikel lesen |
| T1 Energy Inc.: T1 Energy and Corning Deal Accelerates 'Made in America' Solar Momentum | AUSTIN, Texas and CORNING, N.Y., Aug. 15, 2025 (GLOBE NEWSWIRE) -- T1 Energy Inc. (NYSE: TE) ("T1," "T1 Energy," or the "Company") and Corning Incorporated ("Corning," NYSE: GLW) today announced a... ► Artikel lesen |
| Niu Technologies Announces Unaudited Second Quarter 2025 Financial Results | -- Second Quarter Revenues of RMB 1,255.7 million, increase 33.5% year over year -- Second Quarter Net Income of RMB 5.9 million, compared to net loss of RMB 24.9 million in the same period of... ► Artikel lesen |
| Niu Technologies Provides Second Quarter 2025 Sales Volume Update | BEIJING, July 04, 2025 (GLOBE NEWSWIRE) -- Niu Technologies ("NIU", or "the Company") (NASDAQ: NIU), the world's leading provider of smart urban mobility solutions, today provided its sales volume... ► Artikel lesen |
| Niu Technologies Q1 Loss Declines | BEIJING (dpa-AFX) - Niu Technologies (NIU) reported Loss for first quarter of -RMB38.844 millionThe company's earnings totaled -RMB38.844 million, or -RMB0.24 per share. This compares with... ► Artikel lesen |
| Sangamo Therapeutics, Inc.: Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2025 Financial Results | Announced positive topline results from registrational STAAR study in Fabry disease, including positive mean annualized estimated glomerular filtration rate (eGFR) slope at 52-weeks across all dosed... ► Artikel lesen |
| Sangamo Therapeutics, Inc.: Sangamo Therapeutics Announces Positive Topline Results From Registrational STAAR Study in Fabry Disease | STAAR study demonstrated positive mean annualized estimated glomerular filtration rate (eGFR) slope at 52-weeks across all dosed patients in the study, which U.S. Food and Drug Administration (FDA)... ► Artikel lesen |
| Sangamo Therapeutics, Inc.: Sangamo Therapeutics Announces Pricing of $23.0 Million Underwritten Offering | Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced the pricing of an underwritten offering consisting of 12,235,000 shares of its common stock and pre-funded warrants... ► Artikel lesen |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu GREENFIRE RESOURCES LTD finden Sie auf Wallstreet Online.